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Abstract
Background Obstructive sleep apnea is common and associ-
ated with poor outcomes after stroke or transient ischemic
attack (TIA).We sought to determine whether the intervention
strategy improved sleep apnea detection, obstructive sleep ap-
nea (OSA) treatment, and hypertension control among pa-
tients with chronic cerebrovascular disease and hypertension.
Methods In this randomized controlled strategy trial interven-
tion, patients received unattended polysomnography at base-
line, and patients with OSA (apnea-hypopnea index ≥5
events/h) received auto-titrating continuous positive airway
pressure (CPAP) for up to 1 year. Control patients received
usual care and unattended polysomnography at the end of the
study, to identify undiagnosed OSA. Both groups received 24-
h blood pressure assessments at baseline and end of the study.
BExcellent^ CPAP adherence was defined as cumulative use
of ≥4 h/night for ≥70% of the nights.
Results Among 225 randomized patients (115 control; 110
intervention), 61.9% (120/194) had sleep apnea. The strategy
successfully diagnosed sleep apnea with 97.1% (102/105) val-
id studies; 90.6% (48/53, 95% CI 82.7–98.4%) of sleep apnea
was undiagnosed among control patients. The intervention
improved long-term excellent CPAP use: 38.6% (22/57) inter-
vention versus 0% (0/2) control (p < 0.0001). The intervention
did not improve hypertension control in this population with
well-controlled baseline blood pressure: intervention,
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132.7 mmHg (±standard deviation, 14.1) versus control,
133.8 mmHg (±14.0) (adjusted difference, −1.1 mmHg,
95% CI (−4.2, 2.0)), p = 0.48).
Conclusions Patients with cerebrovascular disease and hyper-
tension have a high prevalence of OSA. The use of portable
polysomnography, and auto-titrating CPAP in the patients’
homes, improved both the diagnosis and the treatment for
sleep apnea compared with usual care but did not lower blood
pressure.
Keywords Ischemic stroke .Transient ischemicattack . Sleep
apnea diagnosis . Sleep apnea treatment
Introduction
Obstructive sleep apnea is found in at least half of individuals
who have experienced an acute stroke or transient ischemic
attack (TIA) [1–9]. Sleep apnea has been associated with a
variety of adverse disease states and outcomes including hy-
pertension, diabetes, ischemic stroke and transient ischemic
attacks (TIA), incident coronary events and cardiovascular
mortality, and all-cause mortality [3, 10–14]. Estimates sug-
gest, however, that as many as 70–80% of the patients with
sleep apnea are neither diagnosed nor treated [15]. The bar-
riers to diagnosing and treating sleep apnea involve patient,
provider, and system issues, including access to sleep
laboratory-based testing [15].
The American Heart Association/American Stroke
Association secondary stroke prevention guidelines recom-
mend that patients with ischemic stroke and TIA receive
screening for sleep apnea and treatment because of data sug-
gesting that post-cerebrovascular event patient outcomes are
improved with treatment of sleep apnea [16]. However, this
guideline recommendation has not been adopted widely. For
example, a recent report found that only 6% of the eligible
patients received polysomnography in the year after an index
cerebrovascular event [17].
The BDiagnosis and Treatment of Sleep Apnea in
Cerebrovascular Disease^ (GoToSleep) study evaluated a
strategy to improve the diagnosis and treatment of sleep apnea
among veterans with chronic ischemic stroke or TIAwho also
have hypertension [18]. Specifically, theGoToSleep study was
designed to overcome some of the barriers that existed within
the Veterans Health Administration (VHA) to the timely diag-
nosis and treatment of sleep apnea (e.g., limited mobility,
travel distance) by using home-based ambulatory
polysomnography and auto-titrating continuous positive air-
way pressure (CPAP) to reduce the reliance on laboratory-
based sleep studies. The primary objectives of the
GoToSleep study were to determine whether a diagnostic
and therapeutic intervention strategy among veterans with
chronic cerebrovascular disease and hypertension could
improve: (1) the detection of sleep apnea; (2) the treatment
for obstructive sleep apnea; and (3) the control of
hypertension.
Design and methods
The GoToSleep study was a randomized controlled strategy
trial conducted at two geographically distant Veterans Health
Affairs (VHA) medical centers. The methods of this study
have been described in detail elsewhere [18]. Briefly, patients
with chronic cerebrovascular disease and hypertension were
randomly assigned to an intervention group or a usual care
control group. The randomization was stratified by medical
center, baseline blood pressure, and risk of sleep apnea from
the Berlin Questionnaire [19]. This study (NCT00984308)
received institutional review board approval; patients provid-
ed written informed consent.
Chronic cerebrovascular disease and hypertension patient
definition
Patients were included if they had a history of ischemic stroke
or TIA and either a diagnosis of hypertension or a blood
pressure of ≥140/≥90 mmHg [20]. This study was designed
prior to the revision of the American Heart Association/
American Stroke Association definition of TIA, and
employed the following definitions: an ischemic stroke is a
persistent focal neurological deficit of presumed ischemic or-
igin lasting more than 24 h [21] and a TIA is a focal neuro-
logical deficit of presumed ischemic origin lasting less than
24 h [22]. Brain imaging was not required for the diagnosis of
stroke or TIA. Patients were recruited at least 30 days after
their most recent stroke and at any point after their most recent
TIA.
Measurements
Patient interviews and medical record reviews were conducted
to obtain information about demographics, comorbidities, med-
ication use, and symptoms. Patients were examined to measure
heart rate, neck circumference, height, and weight. The Berlin
Questionnaire was used to classify patients according to Bhigh^
versus Blow^ risk for sleep apnea [19]. Daytime sleepiness was
assessed using the Epworth Sleepiness Scale (ESS) with a score
of ≥10 indicating excessive daytime sleepiness [23, 24].
Neurological functioning was measured with the National
Institutes of Health Stroke Scale (NIHSS) [25, 26].
Blood pressure and antihypertensive medications
Blood pressure measurements were taken at baseline and at
the end of the study with a 24-h ambulatory monitor. Blood
Sleep Breath
pressure data were classified as either sleeping or waking on
the basis of actigraphy data or sleep diary information for
patients with incomplete actigraphy data. Nocturnal blood
pressure dipping patterns were assessed by comparing mean
systolic blood pressure during sleep with mean systolic pres-
sure during the wakeful state [27]. Antihypertensive medica-
tions were not changed as part of the study but were recorded
at the time of the blood pressure measurements. The defined
daily dose (DDD) of all antihypertensive medications was
calculated using the World Health Organization (WHO)
DDD methodology which allows for comparison across anti-
hypertensive regimens [28]. The medication-adjusted mean
systolic blood pressure was calculated from the 24-h mean
systolic blood pressure measurement and the patient’s DDD
as follows: medication-adjusted systolic blood pressure
(SBP) = [mean systolic blood pressure in mmHg] + [the pa-
tient’s DDD × (8.0 mmHg)] [18].
Polysomnography
Intervention patients received full unattended (type 2)
polysomnography at baseline (Safiro, Compumedics,
Victoria, Australia). Control patients received polyso
mnography at the end of the 1-year study period. Nearly all
of the patients received the polysomnography in their homes.
Full unattended polysomnography provided data on electro-
encephalogram (EEG), electrooculogram, chin electromyo-
gram, thoracic and abdominal displacement, airflow, finger
pulse oximeter, electrocardiogram, body position, leg move-
ment, and audio recording of the participant’s snoring. The
polysomnographic data were read centrally and scored ac-
cording to standard criteria [29]. An apnea-hypopnea index
(AHI) was calculated as the number of respiratory events per
hour of sleep [29–31]. Patients with an AHI ≥5 events/h were
diagnosed as having sleep apnea and were offered auto-
titrating CPAP [30]. Patients classified as having central sleep
apnea or Cheyne-Stokes respiration were continued in the
study but were referred for adaptive servoventilation (ASV).
Patients with oxygen desaturations by polysomnography re-
ceived one night of oximetry while using CPAP; patients with
persistent desaturations despite auto-titrating CPAP were pro-
vided supplemental nocturnal oxygen via the CPAP machine.
CPAP adherence support
Our approach to improving CPAP adherence consisted of ear-
ly intensive education and support, followed by regular and
ongoing contact with patients. During the in-home visit where
the results of the baseline polysomnography were reviewed,
staff members provided patients with information about sleep
apnea and CPAP. During the first month after delivery of the
CPAP machine, the patient was visited each of the first 2 days
and then weekly for the first month; thereafter, patients
received monthly telephone calls for the remainder of the 1-
year study period. An in-home visit was scheduled after
6 months of CPAP use and also at the end of the study.
During the in-home visits, staff downloaded pressure, residual
AHI, air leak, and compliance data from the CPAP machine
and reviewed these data with the patients. Staff members were
also available to patients for ad hoc issues related to difficul-
ties with mask fit or other technical problems with the CPAP
machines.
Usual care
Control patients received usual care as directed by their phy-
sicians, including care of their vascular risk factors such as
hypertension and referral for usual care sleep apnea testing.
Control patients in the GoToSleep study were neither
prohibited from nor specifically encouraged to receive
polysomnography as part of their usual care. Control patients
received unattended polysomnography at the end of the study
period.
Outcomes
Sleep apnea diagnosis
The proportion of intervention and control patients with a
diagnosis of obstructive or central sleep apnea was calcu-
lated from the unattended polysomnography performed in
the intervention group and from any polysomnography that
was performed as part of usual care among control patients.
The primary outcome related to sleep apnea detection was
the prevalence of undiagnosed sleep apnea in the control
group which was determined using polysomnography data
obtained as part of the research protocol at the end of the
study.
Obstructive sleep apnea treatment
CPAP adherence was classified as Bnone^ if the patient
refused to take receipt of a CPAP machine or did not use
the machine at all, Bpoor^ if the nights of usage was
≤10% of total nights available, Bsome^ if the total nights
used >10% of total nights available or the cumulative
hours of use was <4 h per night times 70% of the total
nights available for use, and Bexcellent^ if the total cumu-
lative hours of use was ≥4 h per night times 70% of the
total nights available for use [32]. The primary outcome
related to obstructive sleep apnea treatment was the pro-
portion of intervention and control patients with obstruc-
tive sleep apnea with excellent CPAP adherence.
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Hypertension control
The primary hypertension outcome was the final mean 24-h
SBP, adjusted for baseline mean 24-h SBP. Our secondary
hypertension analyses included the final medication-adjusted
SBP, the final DDD, and the proportion of patients with a
nocturnal decline (Bdipping^) in systolic blood pressure of
≥10% [27].
Sample size
The GoToSleep trial was designed to recruit 318 patients
to have at least 80% power to detect the following pre-
specified differences in the three primary aims: 60% of the
intervention patients compared with 10% of the control
patients would be diagnosed with sleep apnea; 50% of
the intervention patients diagnosed with sleep apnea as
part of the study protocol, compared with 15% of the
control patients diagnosed with sleep apnea as part of
usual care, would use CPAP therapy; and the 1-year mean
systolic blood pressure would be 125 mmHg with a stan-
dard deviation of 20 mmHg in the intervention group
compared with 135 mmHg with a standard deviation of
20 mmHg in the control group. The sample size estimates
assumed a 10% loss to follow-up in both the intervention
and the usual care arms.
Analyses
The primary analyses were designed to be intention -to-
treat comparisons of the outcomes for patients in the inter-
vention versus control groups. For the analysis of diagno-
sis rates, all patients were analyzed according to the group
to which they had been randomly assigned regardless of
subject study completion. Ninety five percent confidence
intervals were calculated around the undiagnosed sleep ap-
nea rate obtained from the control group. For the analysis
of treatment rates, CPAP adherence was assessed among
patients with obstructive sleep apnea. The comparison of
final mean 24-h SBP was not restricted to patients with
sleep apnea, but rather was conducted across all patients
with final ambulatory blood pressure data, regardless of
sleep study results. A secondary hypertension control anal-
ysis was pre-specified to be conducted among sleep apnea
patients in the intervention group with or without excellent
CPAP adherence, to examine the effect of CPAP use on
antihypertensive outcomes.
Baseline characteristics were compared between inter-
vention and control groups using Fisher’s exact test, chi-
squared test, 2-sample t test, or Wilcoxon 2-sample tests.
Chi-squared tests were used to test for group differences
in diagnosis and treatment rates. An analysis of covari-
ance (ANCOVA) model, with terms for site, group, and
baseline measure, was used to test for differences in mean
final 24-h SBP. Residual plots were examined for possible
violation of model assumptions. The final medication-
adjusted SBP was analyzed similarly. Final DDD was
rank transformed because of skewness and was analyzed
similarly, including a squared baseline DDD term.
Summary statistics of change in measures are presented
but were not modeled or statistically tested, because the
analyses of the final measurements included adjustment
for baseline measurements. A logistic model with terms
for site and group was used to estimate the effect of the
intervention on the odds of having nocturnal decline of
≥10%. A cumulative logistic model was used for the or-
dinal outcome of nocturnal dipping category and modeled
the probability of having greater nighttime dipping. The
proportional odds assumption was verified. The secondary
analyses of hypertension control measures by CPAP ad-
herence used similar models with the term for treatment
group replaced by a variable for CPAP adherence (excel-
lent versus not). No corrections for multiple comparisons
were made, because we pre-specified a single primary
outcome for the three primary aims. SAS® version 9.2
(Cary, NC) was used for all analyses.
Results
The medical records of N = 2395 patients were screened for
eligibility. Among the N = 1706 (71.2%) potentially eligible
patients, 337 (19.8%) refused and 1144 (67.1%) met at least
one exclusion criterion (Fig. 1). A total of 225 patients were
included in the study: N = 110 intervention and N = 115 con-
trol. Overall, 24/225 (10.7%) patients withdrew: 6 (5.2%)
from the control group and 18 (16.4%) from the intervention
group. The baseline characteristics of the patients are provided
in Table 1.
Sleep apnea diagnosis rate
Polysomnography was conducted at the beginning of the
study on 105 of the 110 intervention patients (Fig. 2); 102/
105 (97.1%) of these studies were valid (three studies had
insufficient high-quality data to be scored). Among the 102
valid studies, 58 (56.9%) had obstructive sleep apnea, 9
(8.8%) had central sleep apnea, and 35 (34.3%) had no sleep
apnea. Polysomnography was completed as part of usual care
in 7 of the 115 control patients (7/115, 6.1%); 5/7 (71.4%) had
obstructive sleep apnea, none had central sleep apnea, and 2/7
(28.6%) had no sleep apnea. Polysomnography was per-
formed at the end of the study, as part of the research protocol,
on 91 control patients; 85/91 (93.4%) were valid studies.
Among the 85 valid studies obtained as part of the study
protocol among control patients, 46 (54.1%) had obstructive
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sleep apnea, 2 (2.4%) had central sleep apnea, and 37 (43.5%)
had no sleep apnea. A total of 53 patients had sleep apnea in
the control group: 51 with obstructive sleep apnea (5 diag-
nosed as part of usual care and 46 diagnosed as part of the
study protocol) and 2 with central sleep apnea (all diagnosed
as part of the study protocol). The prevalence of undiagnosed
sleep apnea (from the control group) was 90.6% (48/53; 95%
CI, 82.7 to 98.4%) (Tables 2 and 3).
Overall (including both intervention and control pa-
tients), 61.9% (120/194) of the patients had obstructive or
central sleep apnea. The ESS was ≥10 in 40/119 (33.6%)
with sleep apnea and 23/75 (30.7%) without sleep apnea
(p = 0.67). The Berlin score was classified as high risk in
85/119 (71.4%) with sleep apnea and 49/75 (65.3%) with-
out sleep apnea (p = 0.37).
Obstructive sleep apnea treatment rate
Among the five control patients who were diagnosed with
obstructive sleep apnea as part of usual care (see Fig. 2),
two patients did not receive CPAP during the study and
one patient had missing CPAP use data. Among the two
control patients with known CPAP use data, 0 (0%) had
excellent CPAP adherence; the mean number of hours
used per night was 0.1 h (standard deviation 0.2); and
the mean proportion of nights with any CPAP use was
0.07 (standard deviation 0.08). In contrast, among the 58
intervention patients who were diagnosed with obstructive
sleep apnea during the study, 1 patient had missing CPAP
use data, 22 (38.6%) had excellent CPAP adherence, the
mean number of hours used per night was 2.5 h (standard
Patients screened for possible eligibility from: 
administrative data and prospective neurology logs
West Haven (n=1546)
Indianapolis (n=849)
Patients not eligible: No ischemic stroke 
or transient ischemic attack history, or no 
high blood pressure or hypertension 
history, or patient not living 
West Haven (n=325)
Indianapolis (n=364)
N=1706 patients potentially eligible:
N=  337 Refused
N=  1144Excluded
Not seen by primary care provider within 18 months (n=54)
Unable to provide own informed consent (n=137)
Age <45 years (n=3)
Hospice, life expectancy <6 months (n=41)
Non-English speaker (n=3)
Away from primary residence too long during study period (n=12)
Oxygen dependent chronic obstructive pulmonary disease (n=16)
Previously diagnosed sleep apnea or polysomnography (n=255)
Other diagnosed sleep disorder (n=12 )
Unable to use face or nasal mask (physical reasons) (n= 4)
Chronic renal failure with dialysis (n= 34)
Primary care provider advised against participation (n=18)
Primary care provider refused permission to contact patient (n=2)
Unable to make contact with the patient (n=566)
225 patients randomized
West Haven (n=115)
Indianapolis (n=110)
Intervention Withdrawal (n=18)
Patient reasons for Withdrawal (n=11)
Not Interested (n=6)
Too busy to participate (n=4)
Illness/hospitalization (n=1)
Withdrawal per protocol (n= 1)
Ineligible (n=1)
Not available / could not contact (n= 5)
Lost to Follow Up (n=5)
Died (n=1)
Control Withdrawal (n=6)
Patient reasons for Withdrawal (n= 4)
Not Interested (n=2)
Too busy to participate (n=0)
Illness/hospitalization (n=2)
Withdrawal per protocol (n= 1)
Ineligible (n=1)
Not available / could not contact (n= 0)
Lost to Follow Up (n=0)
Died (n=1)
110 Intervention
West Haven (n=56)
Indianapolis (n=54)
Withdrew (n=18)
 
115 Control
West Haven (n=59)
Indianapolis (n=56)
Withdrew (n=6)
 
Fig. 1 Patient screening, recruitment, and retention flow
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Table 1 Baseline characteristics
Characteristic Intervention
(N = 110)
Control
(N = 115)
p
value
Age (years): (range), median (45, 91) 70 (50, 90) 70
Mean ± standard deviation 69.7 ± 10.4 70.2 ± 10.1 0.81
White race: N (%) 82 (74.6) 92 (80.0) 0.33
Male sex: N (%) 109 (99.1) 110 (95.7) 0.21
Excessive daytime sleepiness (ESS ≥10): N (%) 36 (32.4) 28 (24.1) 0.17
Index cerebrovascular eventa
Stroke: N (%) 75 (68.2) 87 (75.7) 0.21
Transient ischemic attack (TIA): N (%) 49 (44.6) 45 (39.1) 0.41
Time from most recent event to enrollment (year): (range)
median
(0, 44) 4 (0, 65) 4
Mean ± standard deviation 6.2 ± 7.4 7.3 ± 9.2 0.45
Comorbidity: N (%)
Hypertension 110 (100.0) 115 (100.0)
On any antihypertensive medication 104 (94.6) 111 (96.5) 0.53
Hyperlipidemia 88 (80.0) 96 (83.5) 0.50
Diabetes mellitus 51 (46.4) 40 (34.8) 0.08
Chronic pain 42 (38.2) 31 (27.0) 0.07
Depression 39 (35.5) 37 (32.2) 0.60
Current tobacco smoking: N (%) 32 (29.1) 32 (27.8) 0.83
Chronic obstructive pulmonary disorder (COPD) 26 (23.6) 21 (18.3) 0.32
Myocardial infarction 25 (22.7) 30 (26.1) 0.56
Anxiety 23 (20.9) 13 (11.3) 0.05
Peripheral vascular disease 19 (17.3) 26 (22.6) 0.32
Atrial fibrillation 11 (10.0) 19 (16.5) 0.15
Chronic kidney disease 10 (9.1) 11 (9.6) 0.90
Dementia 10 (9.1) 6 (5.2) 0.26
Congestive heart failure 9 (8.2) 14 (12.2) 0.32
Charlson comorbidity score: mean ± standard deviation 2.6 ± 2.2 2.3 ± 2.2 0.25
Measurements
Neck circumference (inches): mean ± standard deviation 16.4 ± 1.5 16.3 ± 1.3 0.87
Waist circumference (inches): mean ± standard deviation 41.3 ± 5.2 42.2 ± 5.1 0.19
Weight (pounds): mean ± standard deviation 188.6 ± 34.3 193.4 ± 34.7 0.19
Body mass index (kg/m2): mean ± standard deviation 38.5 ± 12.9 39.6 ± 12.9 0.45
NIH Stroke Scale: (range) median (0, 12), 1.0 (0,19), 1.0
Mean ± standard deviation 2.2 ± 2.7 2.0 ± 3.1 0.51
Systolic blood pressure (mmHg): (range) median (86, 184) 132 (94, 190) 134
Mean ± standard deviation 132.1 ± 19.3 133.8 ± 17.3 0.43
Diastolic blood pressure (mmHg): (range) median (36, 100) 72 (50, 102) 72
Mean ± standard deviation 71.6 ± 11.9 72.5 ± 11.3 0.72
24-h mean systolic blood pressure (mmHg): range,
median
(97.2, 176.5)
134.4
(98.7, 178.5)
136.8
Mean ± standard deviation 134.2 ± 14.1 136.1 ± 13.3 0.32
24-h mean diastolic blood pressure (mmHg): range,
median
(51.7, 97.5) 72.0 (51.1, 116.8)
72.2
Mean ± standard deviation 72.3 ± 10.1 73.8 ± 11.4 0.48
Antihypertensive medication defined daily dose (DDD):
(range), median
(0.0, 9.5) 2.7 (0.0, 9.7) 2.7
Mean ± standard deviation 2.9 ± 2.3 3.1 ± 2.3 0.43
Medication-adjusted SBP (mmHg): range, median (116.3, 226.8)
155.0
(100.7, 232.0)
157.4
Mean ± standard deviation 157.4 ± 25.0 161.6 ± 24.3 0.17
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deviation 2.8), and the proportion of nights with any
CPAP use was 0.45 (standard deviation 0.40). The inter-
vention patients were much more likely to have excellent
CPAP adherence than the control patients: 38.6 (22/57)
versus 0% (0/2), p < 0.0001.
Figure 3 provides a graphical illustration of CPAP ad-
herence over time with hours per night used on the y-axis
and nights in the study on the x-axis. These data suggest
that CPAP use varied considerably over time and that
there was no consistent point in time after which CPAP
use stabilized.
Hypertension control
The blood pressure was relatively well controlled at baseline
in this population of patients (Table 1). The baseline mean
110 INTERVENTION
105 Baseline polysomnography as part of study0 Baseline polysomnography as part of usual care 
Continuous Positive Airway Pressure Use
1 Missing
6 None
13 Poor
16 Some
22 Excellent
9 Central sleep apnea
35 No sleep apnea
102 Valid
(3 Invalid)
4 Patient refused
1 Withdrew
58 Obstructive sleep apnea
115 CONTROL
91 Follow-up polysomnography as part of study7 Polysomnography as part of usual care 
Continuous Positive Airway Pressure Use
1 Missing
0 None
1 Poor
1 Some
0 Excellent
2 Central sleep apnea
37 No sleep apnea
85 Valid
(6 Invalid)
12 Patient refused
4 Withdrew
1 Missing 
0 Central sleep apnea
2 No sleep apnea
5 Obstructive 
sleep apnea
46 Obstructive 
sleep apnea
6 Withdrew after beginning CPAP
2 Did not Receive CPAP 
during Study
Fig. 2 Receipt of polysomnography and continuous positive airway pressure
Table 1 (continued)
Characteristic Intervention
(N = 110)
Control
(N = 115)
p
value
Nocturnal blood pressure dipping patterns: N (%)
Extreme: ≥20% fall in SBP at night/sleep 3 (3.1) 5 (4.9) 0.60
Normal: ≥10 but <20% fall in SBP at night/sleep 21 (21.7) 15 (14.6)
None: <10 to ≤0% fall at night/sleep 43 (44.3) 50 (48.5)
Reverse: SBP, sleep >wakefulness 30 (30.9) 33 (32.0)
ESS Epworth Sleepiness Scale, SBP systolic blood pressure
a All patients in this cohort had a history of a cerebrovascular event and hypertension
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24-h systolic blood pressure was 134.2 mmHg (±14.1) for
intervention patients and 136.1 mmHg (±13.3) for control
patients (p = 0.32). The overwhelming majority of patients
(94.6% of the intervention patients and 96.5% of the control
patients, p = 0.53) were taking at least one antihypertensive
medication. The intervention strategy did not significantly
improve blood pressure control; the final mean 24-h systolic
blood pressure was nearly identical in the two groups: inter-
vention, 132.7 mmHg (± standard deviation of 14.1); con-
trol, 133.8 mmHg (±14.0; p = 0.48; Table 4). When
restricting the analysis to intervention patients with sleep
apnea, no difference in the change in mean 24-h systolic
blood pressure was identified for patients with excellent
(−1.1 mmHg) versus not excellent (−1.1 mmHg) CPAP ad-
herence (Table 5). Both final and change in medication-
adjusted 24-h SBP favored the excellent use group, but the
difference between mean final medication adjusted SBP was
not statistically significant (excellent, 149.4 mmHg; not ex-
cellent 166.9 mmHg; p = 0.40).
Discussion
These results demonstrate that sleep apnea is very common
among patients with chronic cerebrovascular disease and hyper-
tension; the observed prevalence of 120/194 (62%) is similar to
rates observed in studies that have primarily focused on acute and
subacute cerebrovascular disease populations [1–9]. These re-
sults also demonstrate that a strategy of diagnosing and treating
sleep apnea in the homes of patientswith chronic cerebrovascular
disease and hypertension can lead to substantial improvements in
the detection of sleep apnea and in treatment with CPAP.
Usual care identified less than one in ten patients who ac-
tually had sleep apnea, a rate that leaves considerable room for
improvement. Moreover, the sleep apnea that was detected in
this study population included some patients with very high
AHIs indicative of severe disease; therefore, it is incorrect to
assume that only mild sleep apnea remained undetected by
usual care. Only 64/225 (28%) participants in this study had
excessive daytime sleepiness according to the Epworth
Sleepiness Scale, indicating that Btypical^ patient characteris-
tics that might alert primary care providers to the need for
performing polysomnography were uncommon. Specifically,
neither the Epworth Sleepiness Scale nor the Berlin
Questionnaire was useful in identifying patients with sleep
apnea in this study. It is unknown whether aging or cerebro-
vascular disease may contribute to a reduced perception of
drowsiness. In the absence of validated and reliable methods
of screening for polysomnography in the post-stroke and post-
TIA populations [33, 34], it is reasonable to use
polysomnography to identify sleep apnea given the high un-
derlying prevalence of sleep apnea in this population and the
known consequences of untreated sleep apnea.
Because testing for sleep apnea was so uncommon in the
usual care group in this study, the number of patients who
were eligible for treatment as part of usual care was very
small; this limited our assessment of CPAP adherence in usual
care versus the intervention groups. None of the usual care
patients used CPAP for the recommended ≥4 h per night for
≥70% of the nights, whereas 38.6% (22/57) of the intervention
Table 2 Polysomnographic data
Characteristic Overall Intervention Control
Number of valid sleep studies (n = 194) (n = 102) (n = 92)a
Apnea-hypopnea index (AHI, events/h): (range) median (0, 87.2) 7.5 (0, 87.2) 7.6 (0, 64.9) 7.3
Mean ± standard deviation 14.3 ± 16.1 15.0 ± 16.6 13.6 ± 15.7
Central apnea index: mean ± standard deviation 2.2 ± 6.7 2.9 ± 8.4 1.3 ± 3.5
Polysomnography results: N (%)
Obstructive sleep apnea 109 (56.2) 58 (56.9) 51 (55.4)
AHI: mean ± standard deviation 21.2 ± 15.6 20.0 ± 15.2 22.6 ± 16.1
Central sleep apnea 11 (5.6) 9 (8.8) 2 (2.2)
No sleep apnea 74 (38.1) 35 (34.3) 39 (42.4)
a The valid sleep studies in the control group include the 85 obtained as part of the study and 7 obtained as part of
routine clinical care
Table 3 Detection of sleep apnea rates
Population Intervention (N = 110) Control (N = 115) p value Difference 95% CI
Sleep apnea identified among all patients 67/110 (60.9%) 5/115 (4.4%) <0.0001 56.6% (46.7, 66.4)
Sleep apnea identified among patients with sleep apnea 67/67 (100.0%) 5/53 (9.4%) <0.0001 90.6% (82.7, 98.4)
Sleep apnea refers to either obstructive or central sleep apnea
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patients achieved this degree of adherence. The two VHA
medical centers differed in their approach to usual care. One
provided CPAP mask fitting and education via a contract with
a home health agency, and the other provided these services
via an on-site durable medical equipment (DME) CPAP clinic.
Both sites provided a visit with a trained sleep staff member
after 30 days, and as-needed support related to mask fit or
equipment functioning. In general, usual care at these two
sites is similar to sleep care received in the non-VHA setting.
The intervention patients, in contrast, had both more frequent
contact with staff and the content of the contact was different
from usual care. In particular, the staff worked with patients to
identify salient motivators for using CPAP (e.g., having more
energy to play with grandchildren) and salient barriers
inhibiting CPAP use (e.g., nasal stuffiness). As the patients
began to use the CPAP, their salient positives and negatives
might have changed, but the staff consistently sought to iden-
tifymethods to overcome those barriers and remind patients of
their individual reasons for trying the CPAP. In this way, the
content of the visits was not only focused on technical issues
related to mask fit, leak, and humidification but also on moti-
vators to try CPAP and to persist over time. In this study,
CPAP adherence was not associated with physical impair-
ments (data not shown). Even patients with hemiparesis and
blindness were able to achieve excellent CPAP adherence with
adequate support from study staff and from caregivers.
This study did not identify a difference in blood pressure
management for intervention versus control patients. Three
key reasons likely contributed to this negative finding. First,
the sample size of this trial was designed to detect a 10-mmHg
difference in mean 24-h systolic blood pressure and this study
did not achieve the anticipated sample size (N = 225 versus
n = 318). Our inability to achieve the targeted sample size was
principally due to delays in hiring and training needed staff
within the VHA human resource constraints and because pa-
tients who were included in the study lived further away from
the medical center than in our pilot work; hence, the resources
needed (e.g., staff time, mileage reimbursement) to provide in-
home polysomnography and CPAP support were greater than
expected. Moreover, several meta-analyses have been pub-
lished since the time of designing this trial which suggest that
the actual difference in systolic blood pressure that can be
expected with CPAP ranges from −1.4 to −7.2 mmHg
[35–38], with most of the estimates closer to the 1.4 mmHg
Fig. 3 Patterns of continuous
positive airway pressure over a
1-year period
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Table 4 Hypertension control: intention to treat analysis
Blood pressure outcomes Intervention
(N = 110)
Control
(N = 115)
Adjusted final means
(standard error)
Adjusted mean
difference (95% CI)
intervention versus
control
p
value
Intervention Control
Final mean 24-h SBP (mmHg): (range), median (102.4, 173.7)
132.0
(107.9, 174.1)
132.9
132.8 (1.2) 133.9 (1.1) −1.1 (−4.2, 2.0) 0.48
Mean ± standard deviation 132.7 ± 14.1 133.8 ± 14.0
Change in mean 24-h SBP (mmHg): (range), median (−44.4, 29.4) −0.5 (−42.9, 26.3)
−0.1
Mean ± standard deviation −2.4 ± 12.5 −1.6 ± 11.3
Final DDD: (range), median (0.0,10.1) 2.5 (0.0,11.5) 2.7 3.1 (0.1) 3.1 (0.1) 0.0 (−0.4, 0.4) 0.51
Mean ± standard deviation 3.0 ± 2.5 3.2 ± 2.2
Change in DDD: (range), median (−3.0, 4.8) 0.0 (−5.0, 5.3) 0.0
Mean ± standard deviation 0.1 ± 1.2 0.0 ± 1.5
Final medication-adjusted SBP (mmHg): (range),
median
(112.8, 240.1)
154.1
(110.0, 248.5)
156.8
158.4 (1.7) 158.7 (1.6) −0.2 (−4.8, 4.4) 0.93
Mean ± standard deviation 157.3 ± 28.2 158.8 ± 25.5
Change in medication-adjusted SBP (mmHg):
(range), median
(−50.6,39.8) −0.2 (−42.9, 45.0) 0.5
Mean ± standard deviation −1.3 ± 16.7 −1.3 ± 15.8
Final nocturnal blood pressure dipping patterns: n
(%)
Odds ratio (95% CI)
Extreme: ≥20% fall in SBP at night/sleep 2 (1.8) 2 (1.7) 0.96 (0.55, 1.71) 0.90
Normal: ≥10 but <20% fall in SBP at night/sleep 16 (14.6) 17 (14.8)
None: <10 to ≤0% fall at night/sleep 40 (36.4) 49 (42.6)
Reverse: SBP at night/sleep greater than
daytime/awake
22 (20.0) 23 (20.0)
Modeling the probability of having greater nighttime dipping
Table 5 Hypertension control: among sleep apnea patients
Blood pressure outcomes Continuous positive airway
pressure adherence
Adjusted final means
(standard error)
Adjusted mean
difference (95% CI)
excellent versus not
p
value
Not excellent
(N = 35)
Excellent
(N = 22)
Not
excellent
Excellent
Final mean 24-h SBP (mmHg): (range), median (109.5, 173.7)
134.4
(102.4, 161.7)
128.8
132.9 (2.4) 131.6 (2.5) −1.3 (−8.1, 5.6) 0.71
Mean ± standard deviation 135.2 ± 13.5 129.5 ± 14.8
Change in mean 24-h SBP (mmHg): (range), median (−23.9, 29.4) 1.2 (−26.6, 18.0)
−0.4
Mean ± standard deviation −1.1 ± 13.1 −1.1 ± 11.2
Final DDD: (range), median (0.2, 10.1) 3.0 (0.0, 9.3) 2.5 3.1 (0.2) 2.9 (0.3) −0.3 (−0.9, 0.4) 0.41
Mean ± standard deviation 3.4 ± 2.5 2.5 ± 2.2
Change in DDD: (range), median (−3.0, 3.1) 0.0 (−3.0, 2.0) 0.0
Mean ± standard deviation 0.0 ± 1.3 −0.3 ± 1.1
Final medication-adjusted SBP (mmHg): (range),
median
(120.0, 240.1)
164.0
(112.8, 236.1)
146.6
161.3 (3.5) 156.9 (3.7) −4.4 (−14.7. 6.0) 0.40
Mean ± standard deviation 166.9 ± 28.4 149.4 ± 25.6
Change in medication-adjusted SBP (mmHg): (range),
median
(−37.4, 39.8) 2.1 (−50.6, 20.5)
−3.2
Mean ± standard deviation 0.6 ± 16.9 −3.3 ± 15.5
Odds ratio (95% CI)
Proportion with final nocturnal decline >10%: N (%) 3 (8.6%) 5 (22.7%) 1.4 (0.6, 3.0) 0.44
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end of the range. A sample size of 167 patients with sleep
apnea in each group would have been required to demonstrate
a 5-mmHg difference in mean 24-h systolic blood pressure
among excellent versus not excellent CPAP users. A much
larger sample size would have been required to identify a
statistically significant relationship between intervention ver-
sus control group patients with a systolic blood pressure
change in the 1.5- to 2.0-mmHg range [35–38]. Second, this
population of veterans with hypertension was treated in the
VHA primary care setting, and the overwhelming majority
was taking antihypertensive medications and their blood pres-
sure was generally very well controlled. The VHA system has
placed an emphasis on hypertension care quality, and blood
pressure management is an important performance measure
within the VHA primary care system nationwide. A recent
study of the effect of CPAP on blood pressure among patients
with resistant hypertension demonstrated a 3.1-mmHg differ-
ence in 24-h systolic blood pressure, but in that study, baseline
blood pressures were approximately 10 mmHg higher than in
our population (24-h systolic blood pressure of 144.2 mmHg)
[39]. Third, we appreciate that hypertension may be attributed
to many causes. Because we did not seek to identify etiologies
of hypertension, we were not able to identify specific patients
in whom sleep apnea may have been the primary etiology of
the hypertension.
The primary limitation of theGoToSleep trial is its focus on
the veteran population, which may limit generalizability to
women as there were relatively few female patients in this
study. The patients in this trial all had a history of cerebrovas-
cular disease and hypertension, so these results should not be
generalized to the acute cerebrovascular event setting—where
sleep apnea may be more prevalent and where hemodynamic
fluctuations may be more prominent [1–9, 13, 40, 41].
Another potential limitation is that although the NIHSS in this
population ranged from 0 to 19, the mean values of approxi-
mately 2 suggest that the population had relatively mild stroke
severity. Therefore, these results may not be generalizable to a
population of chronic cerebrovascular disease patients with
more prominent neurological impairments.
Several randomized clinical trials and observational cohort
studies have examined the use of CPAP in the cerebrovascular
disease population for the purpose of improving post-stroke or
post-TIA outcomes; in general, these studies have focused on
patients in the acute or subacute event setting. The randomized
controlled trials have all been relatively small, with sample
sizes insufficient to identify changes in outcomes associated
with treatment [40, 42, 43]. The largest of the randomized trials
was conducted by Parra et al. [44] and followed (N = 126)
acute stroke patients with sleep apnea over a 2-year period.
The stroke rate was similar in both groups: 3/57 (5.3%) fixed
pressure CPAP and 3/69 (4.3%) control (p = 1.0); however, the
mean time from stroke onset to the first cardiovascular event
was longer in the CPAP group: 15months in the CPAP patients
versus 8 months in the control patients (p = 0.044). Two ran-
domized controlled trials evaluated the use of CPAP in sub-
acute stroke patients and reported mixed results, finding im-
provements in several outcome domains for the CPAP group
(e.g., depression) versus usual care, and also no statistically
significant differences in several outcomes [45, 46].
In conclusion, this study identified both a high prevalence
(62%) of sleep apnea in a chronic post-stroke and post-TIA
population with hypertension and a very low sleep apnea de-
tection rate (9%) for patients in the usual care group. This study
further demonstrated that in-home diagnostic and treatment
strategies can be effectively deployed to supplement sleep
medicine services that are provided in a sleep laboratory.
Although no published data support the use of CPAP among
chronic (as opposed to acute) post-cerebrovascular event pa-
tients specifically for the reduction of vascular events, there is
considerable evidence to support the treatment of sleep apnea
in general to improve a variety of patient outcomes [35, 47].
Our findings add to the growing literature that suggests that the
effect of CPAP on blood pressure is modest and likely only
present in patients with uncontrolled hypertension. The study
results provide a rationale for using polysomnography to iden-
tify sleep apnea among all patients post-stroke or post-TIA
given its high prevalence, and suggest that support for CPAP
adherence should persist over time, because many patients in
the intervention group in this study continued to adapt to CPAP
well beyond the first month of receiving a CPAP machine.
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